Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ARID1A Double Nickase Plasmid (h): sc-400469-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ARID1A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ARID1A Double Nickase Plasmid (h) and ARID1A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ARID1A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ARID1A Antibody (PSG3): sc-32761
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARID1A Double Nickase Plasmid (h) | sc-400469-NIC | 20 µg | $410.00 | |||
ARID1A Double Nickase Plasmid (h2) | sc-400469-NIC-2 | 20 µg | $410.00 |
ARID1A (AT-rich interaction domain 1A) encodes a core subunit of the SWI/SNF (BAF) ATP-dependent chromatin remodeling complex that modulates nucleosome positioning to regulate transcriptional programs. Through control of chromatin accessibility, ARID1A influences enhancer activity, lineage-specifying gene expression, DNA damage responses, and replication-associated processes that shape cell cycle progression and genome stability. ARID1A function intersects with pathways governing epigenetic regulation and stress-responsive transcription, including crosstalk with PI3K/AKT signaling and p53-associated networks. Alterations in ARID1A are frequently observed across human cancers and are widely studied for their impact on chromatin state, transcriptional dysregulation, and tumor suppressor biology.
ARID1A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ARID1A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ARID1A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ARID1A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ARID1A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.